ERBB2 and breast cancer: Down-modulation of miR-181a inhibits TGF-β mediated EMT, invasion and migration, also reverting anoikisis resistance in breast cancer cells; high levels were then associated with shorter disease-free survival of breast cancer patients, who tested negative for ErbB2 amplification [98].